Caption Management’s Arcturus Therapeutics ARCT Stock Holding History

Caption Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-305,400	Closed	-$5.63M	–	1558
2025 Q3	$5.63M	Buy	305,400 +276,500	+957%	+$4.44M	0.04%	451
2025 Q2	$376K	Buy	+28,900	New	+$342K	﹤0.01%	1181
2025 Q1	–	Sell	-30,000	Closed	-$509K	–	1499
2024 Q4	$509K	Buy	+30,000	New	+$565K	﹤0.01%	1103
2024 Q3	–	Sell	-60,000	Closed	-$1.46M	–	1260
2024 Q2	$1.46M	Sell	60,000 -25,000	-29%	-$758K	0.02%	556
2024 Q1	$2.87M	Buy	85,000 +25,000	+42%	+$886K	0.04%	439
2023 Q4	$1.89M	Buy	60,000 +30,000	+100%	+$713K	0.03%	632
2023 Q3	$767K	Buy	+30,000	New	+$924K	0.01%	841
2023 Q2	–	Sell	-30,000	Closed	-$719K	–	1091
2023 Q1	$719K	Buy	+30,000	New	+$538K	0.01%	704
2022 Q4	–	Sell	-30,000	Closed	-$444K	–	1263
2022 Q3	$444K	Hold	30,000	–	–	0.01%	1094
2022 Q2	$472K	Buy	+30,000	New	+$589K	0.01%	1087

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Caption Management's ARCT Position: Q4 2025 in Review

Caption Management sold out of Arcturus Therapeutics (ARCT) in Q4 2025, closing a stake of 58,464 shares — an estimated $1.08M sold.

Caption Management first reported a position in ARCT in Q2 2022 and held it in 4 quarters. The position peaked at $1.08M in Q3 2025. 120 funds tracked by Wall St. Rank hold ARCT as of Q4 2025.

Caption Management reported no remaining Arcturus Therapeutics position as of Q4 2025 after selling out during the quarter.
Caption Management sold 58,464 Arcturus Therapeutics shares in Q4 2025, an estimated $1.08M.
Caption Management first reported a position in Arcturus Therapeutics in Q2 2022 and held it in 4 quarters.
Caption Management's Arcturus Therapeutics position peaked at $1.08M in Q3 2025.
120 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2025.

Based on Caption Management's 13F filing for Q4 2025, filed 17 Feb 2026.